We enrolled patients with a computerised interactive voice response system , and patients were randomly assigned using a permuted block method ( block size of four ) in a 1:1 ratio to receive weekly intravenous paclitaxel ( 80 mg/m ( 2 ) ) plus either weekly masked intravenous placebo or trebananib ( 15 mg/kg ) .